A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Volunteers



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 55
Updated:4/13/2015
Start Date:February 2014
End Date:April 2015
Contact:Pfizer CT.gov Call Center
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Western And Japanese Subjects

This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in
healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days
(Cohorts 1 - 4), 21 days (Cohort 5), or 28 days (Cohorts 6 - 7).


Inclusion Criteria:

- Healthy males and/or female subjects of non childbearing potential between the ages
of 18 and 55 years, inclusive (healthy is defined as no clinically relevant
abnormalities identified by a detailed medical history, full physical examination,
including blood pressure and pulse rate measurement, 12 lead ECG and clinical
laboratory tests).

- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110
lbs).

Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.
We found this trial at
1
site
New Haven, Connecticut 06511
?
mi
from
New Haven, CT
Click here to add this to my saved trials